Healthcare >> CEO Interviews >> July 8, 2002
JOHN LANGSTAFF became President and Chief Executive Officer of Cangene
Corporation on November 1, 1995, when it amalgamated with Winnipeg-based
Rh Pharmaceuticals Inc., a company in which he had been Research
Director, Vice President, Research and Operations, and President and
CEO. Dr. Langstaff has more than 15 years' experience in the business of
biopharmaceuticals.. He has a PhD in Microbiology from the University of
Manitoba. Under his direction, Cangene has been recognized as one of
Canada's best employers, one of Canada's fastest growing companies and
as one of the world's top 100 biotechnology companies. Dr. Langstaff is
actively committed to the development of science and the healthcare
industry in Canada. As well as memberships in various government
healthcare and business committees, and industry organizations, he is a
past Chair of BioNet (a national biotechnology organization), he founded
the Healthcare Products Association of Manitoba and he co-chaired the
Science and Technology Committee for the Economic Innovation and
Technology Council of Manitoba. He has also been recognized as a
distinguished graduate by the University of Winnipeg. Profile
of the company?
Mr. Langstaff: Cangene is a Canadian specialty biopharmaceutical company
that focuses in three areas.
